In my latest article ( about Rapid medical Diagnostic Kits and investing in the industry, I point out the potential for EXAS and their Cologuard test. Here is a link to an article about colorectal cancer, the second most common malignancy among Israeli men and 4th among women. Its prevalence is rising among young adults 20-49 making EXAS a company to consider as a potentially good investment.